MayMag Biologics formerly Tirzepatide Pharma Biopharmaceutical Compounding Industry For FDA Approved Sterile 506e Biologics
Company Description
MayMag Biologics is a Dallas,
Texas-based FDA-registered 506(e) outsourcing facility and full-service contract
development and manufacturing organization (CDMO) specializing in peptide
API synthesis, sterile injectable compounding, biosimilar drug manufacturing,
bacteriostatic water for injection (BWFI), and auto-injection device
production.
As a
registered 506(e) outsourcing facility under the Drug Quality and Security Act
(DQSA), MayMag Biologics operates under direct FDA oversight — distinct from
traditional state-regulated compounding pharmacies. This designation enables
large-scale sterile drug manufacturing for commercial distributors, hospital
systems, and pharmaceutical sponsors nationwide.
Core Manufacturing
Capabilities
Insulin fill-finish
70/30, Glargine, Epinephrine pens and Peptide API Synthesis MayMag Biologics
performs solid-phase peptide synthesis (SPPS) for GLP-1 agonists including
tirzepatide, semaglutide analogs, and custom peptide sequences at clinical and
commercial scale. Our peptide manufacturing capabilities serve pharmaceutical
sponsors seeking a domestic U.S. alternative to offshore API suppliers.
Biosimilar Drug
Manufacturing Our biosimilar CDMO services include compounded formulations of
insulin analogs, GLP-1/GIP dual agonists, and anti-inflammatory biologics. We
manufacture biosimilar products addressing critical national drug shortages
under FDA 506(e) outsourcing facility designation.
Sterile Injectable
Manufacturing MayMag Biologics provides fill-finish manufacturing for sterile
injectables including prefilled syringes, multi-dose vials, and lyophilized
drug products. All sterile manufacturing operations comply with USP Chapter 797
and 800 standards and 21 CFR Parts 210–211.
Bacteriostatic Water for
Injection (BWFI) We manufacture bacteriostatic water for injection (BWFI) in
multi-dose vials for use as a diluent in peptide and protein drug
reconstitution. BWFI production operates under full cGMP compliance and USP
sterility standards.
Auto-Injection Device
Manufacturing MayMag Biologics manufactures epinephrine auto-injectors
(EpiPen-equivalent), insulin pens, and rheumatoid arthritis autoinjectors. Our
automated auto-injection pen manufacturing line addresses critical domestic
supply chain gaps for life-saving emergency medications.
Inhalation Therapeutics
Our inhalation drug product capabilities include metered-dose inhaler (MDI) and
dry powder inhaler (DPI) formulation development and fill-finish manufacturing
for respiratory therapeutics.
Regulatory Credentials
- FDA-registered 506(e) outsourcing facility (DQSA)
- cGMP compliant — 21 CFR Parts 210–211
- GMP Certified
- ISO 13485 certified
- USP Chapter 797 compliant (sterile compounding)
- USP Chapter 800 compliant (hazardous drug handling)
Facilities: MayMag Biologics
operates dual cGMP-certified facilities in the Dallas–Fort Worth metroplex:
- Dallas, Texas — Primary
sterile manufacturing and fill-finish operations
- Garland, Texas — Peptide API
synthesis, quality control, and analytical testing
Both
facilities are FDA-inspected and operate under continuous quality management
systems with full batch record documentation, environmental monitoring, and
third-party audit readiness.
Why MayMag Biologics: The U.S. pharmaceutical
industry's dependence on overseas API supply chains has created significant
risk for patients, sponsors, and healthcare systems. MayMag Biologics was
founded to provide a fully domestic, FDA-inspected alternative — combining the
regulatory rigor of a 506(e) outsourcing facility with the agility and
responsiveness of a specialized CDMO.
Partnership & RFQ Inquiries Visit tirzepatidepharm.com/contact or email cdmo@tirzepatidepharm.com
|
Field |
Value |
|
Careers
Page URL |
|
|
Open
Positions |
Quality Control Analyst, Regulatory Affairs Specialist |
|
Job
Categories |
Pharmaceutical
Manufacturing, Biotechnology, Quality Assurance, R&D |
|
Location |
Dallas,
TX and Garland, TX |
Job Positions:
- Quality Control Analyst — Dallas, TX
- Peptide Synthesis Scientist — Garland, TX
- Regulatory Affairs Specialist — Dallas, TX
Keywords / Tags
506e outsourcing facility, peptide API manufacturer, CDMO, tirzepatide manufacturer, semaglutide, GLP-1 manufacturer, biosimilar CDMO, sterile injectable manufacturer, bacteriostatic water, BWFI, epinephrine auto-injector, insulin pen manufacturer, cGMP contract manufacturer, Dallas Texas pharmaceutical, domestic API manufacturer, 506(e) registration, drug shortage manufacturer, GLP-1 GIP dual agonist
|
Platform |
URL |
|
Website |
|
|
Press
Room |
|
|
Media
Kit |
|
|
Blog |
|
|
Facebook |
Comments
Post a Comment